|
1
|
World Health Organization: https://www.who.int/ionizing_radiation/research/iarc/en/.
March, 2020.
|
|
2
|
Kast K, Rhiem K, Wappenschmidt B, Hahnen
E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M,
et al: Prevalence of BRCA1/2 germline mutations in 21 401 families
with breast and ovarian cancer. J Med Genet. 53:465–471.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kuchenbaecker KB, Neuhausen SL, Robson M,
Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB,
Schmidt MK, Schmutzler RK, et al: Associations of common breast
cancer susceptibility alleles with risk of breast cancer subtypes
in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res.
16(3416)2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gadducci A and Guerrieri ME: PARP
inhibitors alone and in combination with other biological agents in
homologous recombination deficient epithelial ovarian cancer: From
the basic research to the clinic. Crit Rev Oncol Hematol.
114:153–165. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bolton KL, Chenevix-Trench G, Goh C,
Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E,
Barrowdale D, McGuffog L, et al: Association between BRCA1 and
BRCA2 mutations and survival in women with invasive epithelial
ovarian cancer. JAMA. 307:382–390. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chuang YT and Chang CL: Extending
platinum-free interval in partially platinum-sensitive recurrent
ovarian cancer by a non-platinum regimen: Its possible clinical
significance. Taiwan J Obstet Gynecol. 51:336–341. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Du Bois A, Lück HJ, Meier W, Adams HP,
Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, et
al: A randomized clinical trial of cisplatin/paclitaxel versus
carboplatin/paclitaxel as first-line treatment of ovarian cancer. J
Natl Cancer Inst. 95:1320–1329. 2003.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Du Bois A, Reuss A, Pujade-Lauraine E,
Harter P, Ray-Coquard I and Pfisterer J: Role of surgical outcome
as prognostic factor in advanced epithelial ovarian cancer: A
combined exploratory analysis of 3 prospectively randomized phase 3
multicenter trials: By the Arbeitsgemeinschaft Gynaekologische
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe
d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire
(GINECO). Cancer. 115:1234–1244. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921.
2005.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Audeh MW, Carmichael J, Penson RT,
Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN,
Oaknin A, Loman N, et al: Oral poly(ADP-ribose) polymerase
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and
recurrent ovarian cancer: A proof-of-concept trial. Lancet.
376:245–251. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott C, Meier W,
Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in
platinumsensitive relapsed ovarian cancer. N Engl J Med.
366:1382–1392. 2012.
|
|
13
|
Ledermann JA, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott C, Meier W,
Shapira-Frommer R, Safra T, et al: Overall survival in patients
with platinum-sensitive recurrent serous ovarian cancer receiving
olaparib maintenance monotherapy: An updated analysis from a
randomised, placebo-controlled, double-blind, phase 2 trial. Lancet
Oncol. 17:1579–1589. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Pujade-Lauraine E, Ledermann JA, Selle F,
Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A,
Pignata S, et al: Olaparib tablets as maintenance therapy in
patients with platinum-sensitive, relapsed ovarian cancer and a
BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised,
placebocontrolled, phase 3 trial. Lancet Oncol. 18:1274–1284.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Moore K, Colombo N, Scambia G, Kim BG,
Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke
GS, et al: Maintenance olaparib in patients with newly diagnosed
advanced ovarian cancer. N Engl J Med. 379:2495–2505.
2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mirza MR, Åvall Lundqvist E, Birrer MJ,
dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL,
Lund B, Lindahl G, et al: Niraparib maintenance therapy in
platinumsensitive, recurrent ovarian Cancer. N Engl J Med.
375:2154–2164. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Dao F, Schlappe BA, Tseng J, Lester J,
Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan
BY, et al: Characteristics of 10-year survivors of high-grade
serous ovarian carcinoma. Gynecol Oncol. 141:260–263.
2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
McLaughlin JR, Rosen B and Moody J:
Long-term ovarian cancer survival associated with mutation in BRCA1
or BRCA2. J Natl Cancer Inst. 105:141–148. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xu K, Yang S and Zhao Y: Prognostic
significance of BRCA mutations in ovarian cancer: An updated
systematic review with meta-analysis. Oncotarget. 8:285–302.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Drew Y, Ledermann J, Hall G, Rea D,
Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D,
et al: Phase 2 multicentre trial investigating intermittent and
continuous dosing schedules of the poly(ADP-ribose) polymerase
inhibitor rucaparib in germline BRCA mutation carriers with
advanced ovarian and breast cancer. Br J Cancer. 114:723–730.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr:
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J Clin Oncol. 9:389–393.
1991.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Parmar MK, Ledermann JA, Colombo N, du
Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W,
Torri V, et al: Paclitaxel plus platinum-based chemotherapy versus
conventional platinum-based chemotherapy in women with relapsed
ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet.
361:2099–2106. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Bruchim I, Jarchowsky-Dolberg O and
Fishman A: Advanced (>second) line chemotherapy in the treatment
of patients with recurrent epithelial ovarian cancer. Eur J Obstet
Gynecol Reprod Biol. 166:94–98. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Friedlander M, Matulonis U, Gourley C, du
Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R,
Safra T, et al: Long-term efficacy, tolerability and overall
survival in patients with platinum-sensitive, recurrent high-grade
serous ovarian cancer treated with maintenance olaparib capsules
following response to chemotherapy. Br J Cancer. 119:1075–1085.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Alsop K, Fereday S, Meldrum C, deFazio A,
Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, et
al: BRCA mutation frequency and patterns of treatment response in
BRCA mutation-positive women with ovarian cancer: A report from the
Australian Ovarian Cancer Study Group. J Clin Oncol. 30:2654–2663.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Harter P, Hauke J, Heitz F, Reuss A,
Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, et
al: Prevalence of deleterious germline variants in risk genes
including BRCA1/2 in consecutive ovarian cancer patients
(AGO-TR-1). PLoS One. 12(e0186043)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hauke J, Hahnen E, Schneider S, Reuss A,
Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K,
et al: Deleterious somatic variants in 473 consecutive individuals
with ovarian cancer: Results of the observational AGO-TR1 study
(NCT02222883). J Med Genet. 56:574–580. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
González-Martín A, Pothuri B, Vergote I,
DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D,
Hoskins P, Freyer G, et al: PRIMA/ENGOT-OV26/GOG-3012
investigators. niraparib in patients with newly diagnosed advanced
ovarian cancer. N Engl J Med. 381:2391–2402. 2019.PubMed/NCBI View Article : Google Scholar
|
